The PRUNE1 protein, encoded by the PRUNE1 gene, is a member of the phosphoesterase superfamily involved in cellular processes such as migration, proliferation, and differentiation. It regulates signaling pathways, including TGF-β and EGFR, by modulating nucleotide metabolism and interacting with proteins like NME1. PRUNE1 dysfunction is linked to neurodevelopmental disorders, including microcephaly, seizures, and brain atrophy, as well as cancer progression and metastasis.
PRUNE1 antibodies are essential tools for studying its expression, localization, and molecular interactions. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research using these antibodies has revealed PRUNE1's role in tumorigenesis, where its overexpression correlates with poor prognosis in cancers like breast and colorectal. In neurological studies, PRUNE1 antibodies help elucidate mutations causing developmental defects, aiding in mechanistic insights and potential therapeutic strategies.
Commercial PRUNE1 antibodies are typically raised against specific epitopes, such as recombinant protein fragments or synthetic peptides. Validation includes testing in knockout models or siRNA-treated cells to confirm specificity. Their applications extend to clinical research, including biomarker discovery and targeted therapy development, emphasizing PRUNE1's dual significance in cancer and neurobiology.